Silo Pharma Soars 33.98% on Drug Development Milestones

On June 5, 2025, Silo Pharma's stock surged by 33.98% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Silo Pharma has been actively advancing its pipeline of novel therapeutics and drug delivery systems. The company recently announced a partnership with Resyca for an IND-supporting intranasal drug-device study of its PTSD drug, SPC-15. This study is crucial as it aims to deliver the final device data and documentation needed for the planned FDA IND submission, a key milestone in the drug's development process.

In addition to its progress with SPC-15, Silo Pharma has also made strides with its SP-26 ketamine implant. The implant successfully met all endpoints in a fibromyalgia study, demonstrating strong tolerability, sustained drug release, and safety. This positive outcome further solidifies the company's position in the development of non-opioid pain management solutions.

Silo Pharma's intellectual property portfolio has also seen significant expansion. The company has filed multiple patent applications, including one for an exclusively licensed Alzheimer's drug and another for a novel intranasal PTSD treatment. These patent filings not only protect the company's innovations but also open up new avenues for potential revenue streams.

Furthermore, Silo Pharma has been proactive in securing funding to support its development efforts. The company recently closed a $2 million public offering, providing the necessary capital to advance its clinical trials and research initiatives. This financial backing is essential for the company's continued growth and success in the competitive biopharmaceutical industry.